|
|
 |
|
Viewing report
|
|
|
|
Monoclonal Antibodies: 2011
Datamonitor, Oct 2011, Pages: 128
Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 8.2% over 2010-16, outpacing the growth rates of small molecules, therapeutic proteins and vaccines.
Features and benefits
- Strategic dynamics within the sector are broken down by product, company, geography, therapy area, technology type and target.
- The outlook for the sector is compared with other sectors of the pharmaceutical industry: small molecules, therapeutic proteins and vaccines.
Highlights
- While Datamonitor believes biosimilar MAbs will make it onto the major markets, the rate of sales erosion of such a biosimilar MAb will be far less than that experienced by a small molecule upon generic entry.
Your key questions answered
- Assess the outlook for the monoclonal antibodies sector through to 2016
- Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae universe
|
|
|
|
